

Appendix 1. Conflicts of interests

	Weisshaar, Elke	Garcovich, Simone	Ständer, Sonja	Streit, Markus
The Work Under Consideration for Publication				
1	Grant	None	None	None
2	Consulting fee or honorarium	None	None	None
3	Support for travel to meetings for the study or other purposes	None	None	None
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	None	None	None
5	Payment for writing or reviewing the manuscript	None	None	None
6	Provision of writing assistance, medicines, equipment, or administrative support	None	None	None
7	Other	None	None	None
*This means money that your institution received for your efforts on this study.				
Relevant financial activities outside the submitted work				
1	Board membership	Menlo, Trevi	Beiersdorf, Celgene, Galderma, Kiniksa, Menlo, NeRRe, Novartis, Sienna, Trevi	yes
2	Consultancy	Menlo, Trevi, Kiniksa	Beiersdorf, Celgene, Galderma, Kiniksa, Menlo, NeRRe, Novartis, Sienna, Trevi	None
3	Employment	None	None	None
4	Expert testimony	None	None	None
5	Grants/grants pending	None	None	None
6	Payment for lectures including service on speakers bureaus	Münster Pruritus workshop 6.-8.9.2018	None	yes
7	Payment for manuscript preparation	None	None	None
8	Patents (planned, pending or issued)	None	None	None
9	Royalties	None	None	None
10	Payment for development of educational presentations	None	None	None
11	Stock/stock options	None	None	None
12	Travel/accommodations/meeting expenses unrelated to activities listed**	None	None	None
13	Other (err on the side of full disclosure)	Principal Investigator for Menlo and TREVI	Investigator for Dermasense, no honorarium	None
*This means money that your institution received for your efforts.				
**For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.				
Other relationships				
1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	None	None	None

	Gieler, Uwe	Misery, Laurent	Şavk, Ekin	Mettang, Thomas
The Work Under Consideration for Publication				
1	Grant	None	None	None
2	Consulting fee or honorarium	None	None	None
3	Support for travel to meetings for the study or other purposes	None	None	None
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	None	None	None
5	Payment for writing or reviewing the manuscript	None	None	None
6	Provision of writing assistance, medicines, equipment, or administrative support	None	None	None
7	Other	None	None	None
*This means money that your institution received for your efforts on this study.				
Relevant financial activities outside the submitted work				
1	Board membership	Galderma (Rosacea), Lilly (Psoriasis), AbbVie (Psoriasis/Hidra denitis supp), Almirall (Adherence)	Bayer, Lilly Menlo, Novartis, Pierre Fabre, Sanofi, Trevi	None
2	Consultancy	None	Amgen, Bayer Beiersdorf, Celgene, Expanscience, Lilly, Nestlé, Pierre Fabre	None
3	Employment	Univ. Dept Dermatology/University Giessen/Dept. of Dermatology/Hamad Medical Cooperation Doha Qatar	None	None
4	Expert testimony	None	None	None
5	Grants/grants pending	PsoTrain/grant (AbbVie)	BASF, Beiersdorf, Celgene, Clarins, Expanscience, Johnson&Johnson, Pierre Fabre, Uriage	None
6	Payment for lectures including service on speakers bureaus	Galderma, AbbVie, Almirall, Bayer, Beiersdorf, Galderma, GSK, Janssen, Johnson&Johnson, Leo, Lilly Merz, Novartis, Pierre Fabre, Roche, Posay Sandof, Vichy	AbbVie, Bioderma, Celgene, Janssen, Leo, Novartis, Pfizer, Pierre Fabre, Roche-Posay, Sanofi, UCB	FMC – speakers honorary for Peritoneal dialysis
7	Payment for manuscript preparation	Almirall (Adherence Paper Am J Clin Dermatol), Galderma (Burden of Rosacea, submitted)	Beiersdorf, Bioderma, Pierre Fabre, Sanofi	None
8	Patents (planned, pending or issued)	None	None	None
9	Royalties	None	None	None
10	Payment for development of educational presentations	Atopic dermatitis academy Hessen payed by insurance companies	AbbVie, Celgene, Intercept	None
11	Stock/stock options	None	None	None
12	Travel/accommodati ons/meeting expenses unrelated to activities listed**	None	AbbVie, Janssen, Lilly, Novartis, Pfizer, Sanofi	None
13	Other (err on the side of full disclosure)	None	Amgen, Biogen, Galderma, GSK, Janssen, Leo, Lilly, Novartis, Sanofi, Trevi	None
*This means money that your institution received for your efforts. **For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.				
Other relationships				
1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	None	None	None

	Wallengren, Joanna	Dalgard, Florence	Gimenez Armau, Ana	Szepletowski, Jacek C.
The Work Under Consideration for Publication				
1	Grant	None	BAYER Pruritus management in Contact Dermatitis	None
2	Consulting fee or honorarium	None	None	None
3	Support for travel to meetings for the study or None other purposes	None	None	None
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	None	None	None
5	Payment for writing or reviewing the manuscript	None	None	None
6	Provision of writing assistance, medicines, equipment, or administrative support	None	None	None
7	Other	None	None	None
*This means money that your institution received for your efforts on this study.				
Relevant financial activities outside the submitted work				
1	Board membership	None	Uriach, Novartis, Genentech, Sanofi	AbbVie, Celgene, Galenica, Leo Pharma, Pierre-Fabre, Novartis, Menlo, Trevi
2	Consultancy	None	None	Dignity Sciences, Sanzoz
3	Employment	None	None	No
4	Expert testimony	None	None	No
5	Grants/grants pending	None	Uriach, Novartis, Instituto Carlos III-FEDER	No
6	Payment for lectures including service on speakers bureaus	None	Uriach, Novartis, Menarini, Leo-Pharma	AbbVie, Galenica, Janssen, Leo Pharma, Novartis, SunFarm, Sandoz, Eli Lilly
7	Payment for manuscript preparation	None	None	Galenica
8	Patents (planned, pending or issued)	None	None	None
9	Royalties	None	None	None
10	Payment for development of educational presentations	None	Uriach, Novartis, Menarini	None
11	Stock/stock options	None	None	None
12	Travel/accommodati ons/meeting expenses unrelated to activities listed**	None	None	Medac
13	Other (err on the side of full disclosure)	None	None	None
*This means money that your institution received for your efforts. **For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.				
Other relationships				
1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	None	None	Investigator in Clinical Trials: AbbVie, Actelion, Amgen, GSK, Merck, Novartis, Regeneron, Takeda, Trevi

	Lambert, Julien	Leslie, Tabi
The Work Under Consideration for Publication		
1 Grant	None	None
2 Consulting fee or honorarium	None	None
3 Support for travel to meetings for the study or other purposes	None	None
4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	None	None
5 Payment for writing or reviewing the manuscript	None	None
6 Provision of writing assistance, medicines, equipment, or administrative support	None	None
7 Other	None	None
*This means money that your institution received for your efforts on this study.		
Relevant financial activities outside the submitted work		
1 Board membership	Novartis, Leo Pharma, Celgene	None
2 Consultancy	Novartis, Leo Pharma, Celgene	None
3 Employment	None	None
4 Expert testimony	None	None
5 Grants/grants pending	None	None
6 Payment for lectures including service on speakers bureaus	Novartis, Leo Pharma, Celgene	None
7 Payment for manuscript preparation	None	None
8 Patents (planned, pending or issued)	None	None
9 Royalties	None	None
10 Payment for development of educational presentations	None	None
11 Stock/stock options	None	None
12 Travel/accommodati ons/meeting expenses unrelated to activities listed**	Novartis, Celgene	None
13 Other (err on the side of full disclosure)	None	None
*This means money that your institution received for your efforts. **For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.		
Other relationships		
1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	None	Unpaid advisory: Novartis, Menlo